Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk A/S : to Settle US Securities Class Action Lawsuit for $100 Million

09/24/2021 | 10:47am EDT


© MT Newswires 2021
All news about NOVO NORDISK A/S
10/20Cigna's pharmacy benefit unit to prefer cheaper insulin drug from Viatris
RE
10/18NOVO NORDISK A/S : Share repurchase programme - Form 6-K
PU
10/18NOVO NORDISK A/S : – Share repurchase programme
AQ
10/18NOVO NORDISK : Gets a Buy rating from Barclays
MD
10/14NOVO NORDISK : Buy rating from Goldman Sachs
MD
10/12NOVO NORDISK A/S : Share repurchase programme - Form 6-K
PU
10/05NOVO NORDISK A/S : Share repurchase programme (Form 6-K)
PU
10/05Xeris Pharmaceuticals, Inc. completed the acquisition of Strongbridge Biopharma plc fro..
CI
10/04NOVO NORDISK A/S : – Share repurchase programme
AQ
09/28NOVO NORDISK : JP Morgan reiterates its Buy rating
MD
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2021 138 B 21 535 M 21 535 M
Net income 2021 46 476 M 7 278 M 7 278 M
Net cash 2021 6 424 M 1 006 M 1 006 M
P/E ratio 2021 33,5x
Yield 2021 1,47%
Capitalization 1 550 B 242 B 243 B
EV / Sales 2021 11,2x
EV / Sales 2022 10,2x
Nbr of Employees 45 971
Free-Float 69,8%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 677,40 DKK
Average target price 613,52 DKK
Spread / Average Target -9,43%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Executive VP & Head-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S58.77%242 392
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979
MERCK & CO., INC.-0.79%205 421